PBMs: A Mighty Few
Fam Pract Manag. 1998 Jul-Aug;5(7):80.
Pharmacy benefit management companies (PBMs) may indeed have the potential for cutting drug costs, but many worry that they might also have the potential for controlling physicians' prescribing habits. Over half the U.S. population receives drug benefits through PBMs, which often decide which drugs make it onto a formulary and which do not. Eighty percent of this market is controlled by just four PBMs: Medco (owned by Merck), PCS (Eli Lilly), Diversified (SmithKline Beecham) and Caremark (MedPartners).
Source: Pharmacy benefit management: savings or shackles? Health Care Business Digest. 1998;3(3):36–41.
Copyright © 1998 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact email@example.com for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions
More in FPM
Related Topic Searches
MOST RECENT ISSUE
Access the latest issue
of FPM journal
To avoid a negative payment adjustment from Medicare in 2020, practices must achieve a MIPS final score of at least 15 points for the 2018 performance period. Here's how to meet this performance threshold.